Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amazing numbers and expected now that we have a winning drug!
Thanks!
Well Dr.Bhatt sorta said this in a recent article about lipids, Triglycerides specifically. At least he mention Vascepa could benefit patients with normal Triglyceride levels, but still waiting on the EPA/AA ratio conversation. I think he is really fixated on EPA now and seems to be glossing over more materials. So any day now the conversation will change.
By the way have any EPA/AA ratio graph's/data for the various events, been released from Reduce-it trial looking forward to graphs in relationship to patient CVD even risk.
great graph..thanks for the snapshot. I was graphing scripts for a long time in excel, but stopped sometime ago.
He's finally catching on. It's not about lipid lowering.
You might consider purchasing some shares, PPS will return promptly. This a temporary low. I bought some a few months ago and made some quick cash. I may do it again.
Remember Baker Brothers recently added large number of ACAD shares recently. So they most see some future value here.
~39 Million shares
Not really look at ACAD they report their earnings call, marketeers realize the EPS will be way negative stock dropped a buck and a half. EPS is a big driver but of course other factors can come in play.
Once we are cash flow positive the PPS will move, not until then. We really need to see a positive EPS. Marketeers only understand positive earnings and nothing else matters.
The Market and Amarin are as unpredictable as our insane leader!
Thanks north great article.
Indian poker is the funniest version after a few drinks.
The FDA inspects and approves biomedical/drug manufacturers/ suppliers of the drugs or devices and are responsible safety and quality of drugs and devices. Event though the state licensed you to do business the FDA can shut you down of your not meeting quality control standards.
FDA safeguards the integrity of the drug supply chain through initiatives that help protect consumers from exposure to substandard drugs and ensure that safe and effective drugs reach U.S. consumers.
I know I was involved in FDA inspections we manufactured biomedical equipement and repackaged electrodes for resale and supplied all of the above to Physical Therapist's, Hospitals and Researchers.
Actually not very complicated, the logistics are fairly simple. They have a drug everyone wants and needs. The suppliers ship the drugs to pharmacies and hospitals. The patients places an order with the pharmacy via script. The pharmacy provides the patient with the order, if not in stock, they order from supplier. Amarin only needs to make sure the supply line has the stock available for the demand, which is the biggest problem. The FDA approves the suppliers by the way. Of course marketing play's a role for a short time, but eventually this will be a well known drug by every physician out there.
Cardiologist should know him if they follow the AHA and ACC meetings, not to mention Vascepa. Seems Cardiologist around the work are becoming familiar with both.
Actually I knew nothing about Dr. Bhatt the person, until the many interviews regarding the Reduce-It trial result. Since the AHA and ACC there may only be a handful around the world that don't know his name.
He is a house hold name when it comes to heart disease.
Maybe before AHA meeting. If they don’t know him now, they certainly are out of touch with what’s going on!
Thanks for this - lot's of interest for Vascepa world wide already.
What a day:
Last Price
$20.76
Today’s Change
+2.32 (+12.58%)
Bid x Size
20.77 x400
Ask x Size
20.85 x200
Day’s Range
18.26 - 20.90
Volume
22,556,219
Love it when we are on a tear....hope it sticks.
just play the volatility. This movement is not based on a rumor.
No shortage of stupid predictions.
Yes very true! These experts really should be ashamed of themselves for such sloppy research and decision making.
The researchers that designed the VITAL study proved it once again.
When will they learn? I believe they forgot the basic's, dosages seem to be an integral part of medicine. This is why Vascepa was so successful including the single component of O3 EPA as the primary component which reduced CVD risk.
Wrong about what?
Yes what EMA report is 1 gram O3 Mixed DHA/EPA dosage does nothing.
The professionals who ran VITAL study should have know better, with some research!
VITAL – The VITamin D and OmegA-3 TriaL (VITAL) was designed to test the role of vitamin D and omega-3 fatty acid supplementation in the primary prevention of cardiovascular disease and cancer.
Study Description
Go to
Brief Summary:
The VITamin D and OmegA-3 TriaL (VITAL) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses.
Yes, I didn't expect any details! In-Play message yesterday around 5:00.
Amarin Earnings Summary estimates for next quarter. With script's climbing another easy beat as far as revs go.
Next Earnings Date: 5/3/19
The consensus of the 3 analysts covering AMRN for 1st quarter 2019 is a per share value of USD -.10.
Mean Estimate: USD -0.103
High Estimate: USD -0.06
Low Estimate: USD -0.14
Revenue
Next Earnings Date: 5/3/19
AMRN reported 4th quarter 2018 Revenue of USD 77.3M on 2/27/19.
PS These haven't been revised yet. But 1st Quarter results, we will beat revs easily. They just need to tone down spending, cutting out T.V. advertising should help.
Thanks ziploc_1. It's a great think he took a look and like what he saw.
Ridiculous. They should march to ban Soda vending machines from schools.
Yea ha! Well time to go home and relax. Nice way to end the day.
yes this is great news. We should see our PPS back to where it should be or higher.
That's correct they should apologize. Then welcome him to the board of trustee's.
I would no be surprised they are buying as we speak.
I know, their not the sharpest tools in the shed!
I wonder if they discover an association if CVD rick with AA/EPA ratios in Reduce-it trial? Perhaps a better risk indicator for screening CVD risk in patients.
The marketeers must be reading the ADA paper.
I hoping when Dr. Nissen has his ADCOM. The FDA invites Dr. Bhatt to be on the panel. :>)
I'm glad to hear this, I was wrong about you, I assumed you did not want to prescribe Vascepa for primary care. I'm just making the case against the ADCOM panel, more on the side of FDA decision process, not against you. I wish the FDA would think like doctors rather than politicians. I think Mary Parks's was grandstanding and blind sided the boy's from Amarin.
I like you, you bring up some good point's to the board. It's nice to have a Cardiologist on the board. I agree that marketing and educating Cardiologist about Vascepa should the primary focus and then PCP's, PA's etc's.
Is it true in a number Statin trials have shown poor results in primary prevention and typically better results in secondary?
Is this because once you have a heart attack, your chances of another event climb dramatically?
Yes of course while people dying from heart disease waiting for CVOT focused on primary prevention trial to run it's course. Think of the children that have lost their parent's and grand parents because of egos in the medical community, certainly the FDA at he ADCOM. They ignored the evidence presented to them. A lot of excuses where flung around and across the table why the Jelis trial was invalid. Oh it's a Japanese trial or not blinded, more statin's would do the same thing. If the medical establishment opened their eye's and realized why the Japanese have the lowest CVD risk in world...hint AA/EPA ratios as close to 1:1 as you can get. In the U.S. only a few Physicians understand the value of AA/EPA ratios.
I think there is enough evidence the drug works and is very safe. I could understand your case, if risk outweighed a drugs effectiveness.
Any Doctor with a heart would prescribe Vascepa to a patient with CVD risk. You might save a few kids from broken heart!
I think Vascepa acting as a key anti-inflammatory driver in human biology expands past a single disease. Your primary focus is CVD. It would be foolish to assume Vascepa would be useless in in primary prevention. Sure you need proof 'Statistics'. Like the FDA and the ADCOM expert's who ignored the science of EPA and CVD risk reduction available, the nay sayer's. Dr. Deepak Bhatt was one of these and had a double take regarding the Japanese Jelis intervention study and changed his view regarding this trial.
Let's say the upcoming results from the Evaporate trial reduces plaque by a significant amount, would this be enough?
I believe it's a good idea to distance ourselves from Triglycerides lowering as much as possible. It's clear this is a CVD event lowering drug with many MO's. RRR relationship to Trig levels?
In REDUCE-IT, CV benefits appeared similar across baseline levels of triglycerides (less than versus greater than or equal to 150 mg/dL or 200 mg/dL).
Additionally, the reduction in major adverse CV events with VASCEPA appeared to occur irrespective of an achieved triglyceride level above or below 150 mg/dL at one year, suggesting that the CV risk reduction was not tied to achieving a more normal triglyceride level.
These observations suggest that at least some of the impact of VASCEPA on the reduction in ischemic events may be explained by metabolic effects other than triglyceride lowering.